DSpace Repository

Treatment of tungiasis using a tea tree oil-based gel formulation: protocol for a randomised controlled proof-of principle trial

Show simple item record

dc.contributor.author Kigen, Gabriel
dc.contributor.author Abrha, Solomon
dc.contributor.author Kosari, Sam
dc.date.accessioned 2022-10-19T09:27:06Z
dc.date.available 2022-10-19T09:27:06Z
dc.date.issued 2021
dc.identifier.uri http://ir.mu.ac.ke:8080/jspui/handle/123456789/6950
dc.description.abstract Introduction Tungiasis (sand flea disease or jigger infestation) is a neglected tropical disease caused by penetration of female sand fleas, Tunga penetrans, in the skin. The disease inflicts immense pain and suffering on millions of people, particularly children, in Latin America, the Caribbean and sub-Saharan Africa. Currently, there is no standard treatment for tungiasis, and a simple, safe and effective tungiasis treatment option is required. Tea tree oil (TTO) has long been used as a parasiticidal agent against ectoparasites such as headlice, mites and fleas with proven safety and efficacy data. However, current data are insufficient to warrant a recommendation for its use in tungiasis. This trial aims to generate these data by comparing the safety and efficacy of a 5% (v/w) TTO proprietary gel formulation with 0.05% (w/v) potassium permanganate (KMnO4) solution for tungiasis treatment.Methods and analysis This trial is a randomised controlled trial (RCT) in primary schools (n=8) in South Western Kenya. The study will include school children (n=88) aged 6–15 years with a confirmed diagnosis of tungiasis. The participants will be randomised in a 1:1 ratio to receive a 3-day two times a day treatment of either 5% TTO gel or 0.05% KMnO4 solution. Two viable embedded sandflea lesions per participant will be targeted and the viability of these lesions will be followed throughout the study using a digital handheld microscope. The primary outcome is the proportion of observed viable embedded sand fleas that have lost viability (non-viable lesions) by day 10 (9 days after first treatment). Secondary outcomes include improvement in acute tungiasis morbidities assessed using a validated severity score for tungiasis, safety assessed through adverse events and product acceptability assessed by interviewing the participants to rate the treatment in terms of effectiveness, side effects, convenience, suitability and overall satisfaction en_US
dc.language.iso en en_US
dc.publisher BMJ en_US
dc.subject Tungiasis en_US
dc.title Treatment of tungiasis using a tea tree oil-based gel formulation: protocol for a randomised controlled proof-of principle trial en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account